All 3 efficacy endpoints met the 10 % noninferiority margin : the primary composite endpoint ( 80.1 % vs 82.9 % ; 95 % confidence interval [ CI ] , -7.5 to 2.0 ) , investigator-assessed clinical cure ( 82.7 % vs 80.5 % ; 95 % CI , -2.6 to 7.0 ) , and proportion of patients attaining 20 % reduction in lesion area ( 85.9 % vs 85.3 % ; 95 % CI , -3.7 to 5.0 ) for oritavancin vs vancomycin , respectively .